AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
Address: Mexico
Tel: 01 800 06(55) 53 74 96 00
Web: http://www.astrazeneca.com.mx/
biopharmaceutical company. For patients and physicians, they provide medicines for some of the world’s most serious diseases. For the people who pay for healthcare, they work to make sure that their medicines offer real value for money. For their employees, they provide a culture in which they can feel appreciated, energised and rewarded for their contribution. For the shareholders they aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, they want to be valued for the contribution our medicines can make to society and trusted for the way in which they do business. They work closely with all their stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.
prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Please can you tell us in your own words how you’ve seen the Mexican pharmaceutical market change over the past five years? Mexico is one of the top ten markets…
You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time?…
Please can you give us a brief rundown of Pierre Fabre’s activities in Mexico since they opened an affiliate here, specifically the company’s milestones and achievements along the way? Pierre…
Since we last spoke to you in 2008, Mexico has undergone a lot of regulatory changes, and we witnessed the rise of Seguro Popular, and the rise of COFEPRIS for…
Grünenthal first started operations in Mexico back in 1998, we then interviewed Mr. Klaus Kuchen in 2005, but we want to know what’s happened since. Please can you give us…
There are about 250 employees and you have regional presence in Latin America. In your view as CEO, can you tell our readers about the biggest growth drivers and challenges…
You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here 11 years ago? The…
Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way? Shire started operations in…
Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When Octapharma first came to…
From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years?…
See our Cookie Privacy Policy Here
